Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined
Abroad (travel likely)RecruitingEARLY_PHASE1
Conditions
Myelofibrosis，MF
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The University of Kansas Cancer Center, Fairway, Kansas, United States
Contact: Study coordinator (Dr. Abdulraheem Yacoub Professor Hematology Medicine, MD) · ayacoub@kumc.edu
Study leads
Abdulraheem Yacoub, Doctor of Medicine
Principal Investigator
University of Kansas Medical Center